reconstitution raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-07-23 and is reviewed periodically as new material appears.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 4963 Da for full-length thymosin beta-4 | Value applies to the parent protein; fragment products may differ |
| Appearance | White to off-white lyophilized powder | Typical form of supplied synthetic peptide |
| Solubility | Freely soluble in water | Polar peptide; dissolves readily in aqueous buffer |
| Storage of dry powder | −20 °C, desiccated, protected from light | Standard laboratory practice for peptides |
| Typical detection method | Liquid chromatography–tandem mass spectrometry | Used in purity testing and anti-doping analysis |
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
A more recent paper-based microfluidic design utilized a sensor, consisting of fluorescently labeled single-stranded DNA (ssDNA) coupled with graphene oxide, on its surface to simultaneously detect heavy metals and antibiotics in food products. Heavy metals increased fluorescence intensity, whereas antibiotics decreased fluorescence intensity. Recently, paper-based devices have become very attractive for making inexpensive, disposable and convenient analytical devices for the determination of reactive phosphate in water. These devices utilize the molybdenum blue protocol for phosphate detection.
== Antagonists == Growth hormone receptor antagonists such as pegvisomant (trade name Somavert) are used in the treatment of acromegaly. They are used if the tumor of the pituitary gland causing the acromegaly cannot be controlled with surgery or radiation, and the use of somatostatin analogues is unsuccessful. Pegvisomant is delivered as a powder that is mixed with sterilized water and injected under the skin.
Dinoflagellates are the primary source of dinosteral. Dinoflagellates are unicellular, aquatic organisms that live in both marine and inland environments and are a prominent constituent of phytoplankton. Dinoflagellates are often characterized by their uncommon sterol distribution, dominated by 4α-methyl sterols derived from lanosterol rather than cycloartenol. In many cases, the most abundant sterol in dinoflagellates is dinosterol. Dinosterol is often used a biomarker in geochemical research because it is produced almost exclusively by dinoflagellates and is found in many environments. In addition to several species of dinoflagellates, dinosterol has also been isolated from the diatom Nivicula sp. (CS-46c) collected from Port Hacking, New South Wales, Australia.
For services to Broadcasting and to Charity. Jacqueline Blake. Lately Chair, LACA, The Food People. For services to Education. Christopher John Blandford. President, World Heritage UK. For services to World Heritage. Heather Jane Boardman. Adviser, British Fashion Council and Founder, British Beauty Council. For voluntary services to Fashion and Beauty. Professor Daniela Bortoletto. Head of Particle Physics, University of Oxford. For services to Particle Physics and to Gender Equality. Camilla Jane Bowry. Founder and Chief Executive Officer, Sal's Shoes. For services to Young People, to Education and to the Environment. Michael Andrew Boyd. Project Manager, Northern Ireland Human Rights Commission, Consultant Director for Northern Ireland, Rio Ferdinand Foundation, Chair, Belfast Healthy City and lately Director, Football Development, Irish Football Association. For services to Association Football, to Sport, to Charity and to Reconciliation in Northern Ireland. Eamonn John Boylan. Chief Executive, Greater Manchester Combined Authority. For services to Local Government. Anthony James Bravo. Principal, Basingstoke College of Technology. For services to Further Education. Dr. Stephen Brierley. Founder, Riverlane. For services to Quantum Computing. Millie Bright. Footballer. For services to Association Football. Professor Matthew Jon Brookes. Professor of Physics, University of Nottingham. For services to Physics. Abigail Margaret Brown. Councillor and lately Leader, Stoke-on-Trent City Council, and Deputy Chair, Local Government Association. For services to Local Government.
The 21st Century Cures Act enacted in December 2016 allows researchers to waive the requirement for informed consent when clinical testing "poses no more than minimal risk" and "includes appropriate safeguards to protect the rights, safety, and welfare of the human subject." The probability that a patient may sue researchers who utilize tissues that would typically be discarded is low, but as genetic research becomes more prevalent, this likelihood may increase. Ideally, researchers should obtain informed consent from individuals and aim for transparency in their intended use of the human tissue while protecting the privacy of the donor. CAP and other laboratory accreditation organizations (AO) have additional requirements and protocols for repurposing biospecimens that would otherwise be discarded. In July 2011, an Advance Notice of Proposed Rule Making (ANPRM), entitled "Human Subjects Research Protections: Enhancing Protections for Research Subjects and Reducing Burden, Delay, and Ambiguity for Investigators" was published in the Federal Register. The rise in direct-to-consumer (DTC) genetic testing has raised concerns about the secondary use of both patient samples and their data.
Sources: en.wikipedia.org
CPA is available in the form of oral tablets alone (higher-dose; 10 mg, 50 mg, 100 mg) or in combination with ethinylestradiol or estradiol valerate (low-dose; 1 or 2 mg CPA) and in the form of ampoules for intramuscular injection (higher-dose; 100 mg/mL, 300 mg/3 mL; brand name Androcur Depot). The higher-dose formulations are used to treat prostate cancer and certain other androgen-related indications while the low-dose formulations which also have an estrogen are used as combined birth control pills and are used in menopausal hormone therapy for the treatment of menopausal symptoms.
=== Angiofibromas === Sirolimus has been used as a topical treatment of angiofibromas with tuberous sclerosis complex (TSC). Facial angiofibromas occur in 80% of patients with TSC, and the condition is very disfiguring. A retrospective review of English-language medical publications reporting on topical sirolimus treatment of facial angiofibromas found sixteen separate studies with positive patient outcomes after using the drug. The reports involved a total of 84 patients, and improvement was observed in 94% of subjects, especially if treatment began during the early stages of the disease. Sirolimus treatment was applied in several different formulations (ointment, gel, solution, and cream), ranging from 0.003 to 1% concentrations. Reported adverse effects included one case of perioral dermatitis, one case of cephalea, and four cases of irritation. In April 2022, sirolimus was approved by the FDA for treating angiofibromas.
Hormone replacement therapy (HRT) is primarily concerned with alleviating gender dysphoria in transgender people. Hormone therapy targets the secondary sex characteristics. Trans women typically use feminizing therapy, the goal of which is to develop female characteristics while suppressing male characteristics. Trans men typically use masculinizing therapy, which has the opposite goal – to develop male characteristics while suppressing female characteristics. Trans women are usually treated with estrogen and complementary anti-androgenic therapy. According to UCSF Transgender Care, "The primary class of estrogen used for feminizing therapy is 17-beta estradiol, which is a 'bioidentical' hormone in that it is chemically identical to that from a human ovary." The anti-adrogenic medications include spironolactone and the 5-alpha reductase inhibitors, finasteride and dutasteride. This therapy induces breast formation, reduces male hair pattern growth, and changes fat distribution, also leading to a decreased testicular size and erectile function. Trans men are normally treated with exogenous testosterone. Several formulations of testosterone exist, and in the U.S., all formulations are "bioidentical" to endogenous testosterone of testicular origin. Masculinizing therapy is expected to cease menses, to increase facial and body hair, to cause changes in skin and in fat distribution, and to increase muscle mass and libido.
Testing of tissue remains the most definitive way of confirming the diagnosis of CJD, although even a biopsy is not always conclusive. In one-third of people with sporadic CJD, deposits of "prion protein (scrapie)", PrPSc, can be found in the skeletal muscle or the spleen. Diagnosis of vCJD can be supported by biopsy of the tonsils, which harbor significant amounts of PrPSc; however, biopsy of brain tissue is the definitive diagnostic test for all other forms of prion disease. Due to its invasiveness, a biopsy will not be done if clinical suspicion is sufficiently high or low. A negative biopsy does not rule out CJD, since it may predominate in a specific part of the brain. The classic histologic appearance is spongiform change in the gray matter: the presence of many round vacuoles from one to 50 micrometers in the neuropil, in all six cortical layers in the cerebral cortex, or with diffuse involvement of the cerebellar molecular layer. These vacuoles appear glassy or eosinophilic and may coalesce. Neuronal loss and gliosis are also seen. Plaques of amyloid-like material can be seen in the neocortex in some cases of CJD. However, extra-neuronal vacuolization can also be seen in other disease states. Diffuse cortical vacuolization occurs in Alzheimer's disease, and superficial cortical vacuolization occurs in ischemia and frontotemporal dementia. These vacuoles appear clear and punched out. Larger vacuoles encircling neurons, vessels, and glia are a possible processing artifact.
Sources: en.wikipedia.org
=== Impact on nutrition === The introduction of refrigeration allowed for the hygienic handling and storage of perishables, and as such, promoted output growth, consumption, and the availability of nutrition. The change in our method of food preservation moved us away from salts to a more manageable sodium level. The ability to move and store perishables such as meat and dairy led to a 1.7% increase in dairy consumption and overall protein intake by 1.25% annually in the US after the 1890s. People were not only consuming these perishables because it became easier for they themselves to store them, but because the innovations in refrigerated transportation and storage led to less spoilage and waste, thereby driving the prices of these products down. Refrigeration accounts for at least 5.1% of the increase in adult stature (in the US) through improved nutrition, and when the indirect effects associated with improvements in the quality of nutrients and the reduction in illness is additionally factored in, the overall impact becomes considerably larger. Recent studies have also shown a negative relationship between the number of refrigerators in a household and the rate of gastric cancer mortality.
=== Pollution remediation === NASA's microencapsulating technology enabled the creation of "Petroleum Remediation Product," (PRP) which safely cleans petroleum-based pollutants from water. PRP uses thousands of microcapsules—tiny balls of beeswax with hollow centers. Water cannot penetrate the microcapsule's cell, but oil is absorbed into the beeswax spheres as they float on the water's surface. Contaminating chemical compounds that originally come from crude oil (such as fuels, motor oils, or petroleum hydrocarbons) are caught before they settle, limiting damage to ocean beds. PRP microcapsules serve as nutrients to assist naturally occurring microbes in soil or water to biodegrade contaminants.
== Ownership == The Nobel Institute places no restrictions on the ownership of the medal and the accompanying diploma and prize money once it has been awarded to the recipient. If the recipient chooses not to keep them, they may be sold, donated, or given away. The dedicatee cannot be changed and the prizes cannot be revoked.
Thymocytes and thymic epithelial cells have different developmental origins. The epithelium of the thymus develops first, appearing as two outgrowths, one on either side, of the third pharyngeal pouch. It sometimes also involves the fourth pharyngeal pouch. These extend outward and backward into the surrounding mesoderm and neural crest-derived mesenchyme in front of the ventral aorta. Here, the thymocytes and epithelium meet and join with connective tissue. The pharyngeal opening of each diverticulum is soon obliterated, but the neck of the flask persists for some time as a cellular cord. As the cells lining the flask proliferate further, cell buds form; they become surrounded and isolated by the invading mesoderm. The epithelium forms fine lobules and develops into a sponge-like structure. During this stage, hematopoietic bone-marrow precursors migrate into the thymus. Normal development is dependent on the interaction between the epithelium and the hematopoietic thymocytes. Iodine is also necessary for thymus development and activity.
Sildenafil is available as a generic drug in the United States, labeled for pulmonary arterial hypertension, and to treat erectile dysfunction, as the patent expired in April 2020. In the US, Revatio and Viagra are marketed by Viatris after Upjohn was spun off from Pfizer.
Sources: en.wikipedia.org
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.
No. No major regulatory authority lists an approved product under this name, and no pharmacopoeial monograph exists for it. Material sold under the label is therefore supplied outside approved pharmaceutical channels, which affects the quality documentation available.
It falls within a prohibited class covering peptide hormones and growth factors, based on presumed effects on tissue repair and blood vessel formation. Anti-doping laboratories have published mass spectrometry methods for detecting thymosin beta-4 related peptides in urine samples.
Standard practice is a desiccated container at −20 °C, protected from light and kept sealed between uses. Letting the vial reach room temperature before opening reduces condensation on the powder. Repeated warming and cooling of the whole container is generally avoided.